To address this challenge, a number of recent studies have identified novel selective AhR modulators (SAhRMs) [10] or utilized drugs currently in use in the clinic and with a previously unappreciated capacity to activate the AhR, as candidates for anti-cancer therapeutics in breast cancer and melanoma [11, 12]. The gene discussed is AHR; the disease is breast cancer.